Investigational drug · Phase 2
Antithymocyte globulin
Also called: ATG
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Transplant Rejection, Renal Transplantation.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
563
Any phase or sponsor naming "Antithymocyte globulin"
First trial start
2022
Jun 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Antithymocyte globulin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Transplant Rejection
- Renal Transplantation
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Antithymocyte globulin" as an intervention, largest first.
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01949129 · 1,800 participants (planned) · Start Apr 2013 · Primary completion Jun 1, 2030
Drug: VP16; Thiotepa and 6 more · For: Acute Lymphoblastic Leukaemia
Sites: Buenos Aires, Argentina; La Plata, Argentina; Melbourne, Australia · 119 sites in all
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationPivotal-lookingCompleted
Hospital do Rim e HipertensãoAcademic, hospital or other
NCT03468478 · 1,209 participants · Start Jun 18, 2017 · Primary completion Mar 18, 2021
Drug: Sirolimus; Everolimus and 1 more · For: Kidney Transplant Infection
Sites: São Paulo, Brazil
Klemens BuddeAcademic, hospital or other
NCT02558452 · 1,000 participants (planned) · Start Dec 2016 · Primary completion Jan 2027
Drug: Tacrolimus once daily (Advagraf) · For: Graft Failure; Death; Acute Rejection of Renal Transplant and 7 more
Gang ChenAcademic, hospital or other
NCT06087003 · 958 participants · Start Mar 3, 2013 · Primary completion Jul 27, 2022
Drug: Basiliximab Injection; rabbit ATG · For: Kidney Transplant Rejection; Pediatric Kidney Disease
Sites: Guangzhou, China; Zhengzhou, China; Hangzhou, China · 5 sites in all
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT02487069 · 876 participants · Start Jun 2015 · Primary completion Jan 31, 2020
Drug: Cyclosporin A; Methotrexate and 2 more · For: Acute Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome
Sites: Guangzhou, China
- GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATGPivotal-lookingActive, not recruiting
DKMS gemeinnützige GmbHAcademic, hospital or other
NCT05153226 · 640 participants · Start Mar 2, 2022 · Primary completion Mar 31, 2026
Drug: Cyclophosphamide; ATG · For: Graft Vs Host Disease; Peripheral Blood Stem Cell Transplantation; AML and 3 more
Sites: Aachen, Germany; Augsburg, Germany; Chemnitz, Germany · 23 sites in all
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney TransplantationPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07412470 · 526 participants (planned) · Start Mar 13, 2026 · Primary completion Aug 15, 2029
Drug: Frexalimab; Frexalimab and 6 more · For: Kidney Transplant Rejection
Sites: San Francisco, California; Atlanta, Georgia; Hines, Illinois · 73 sites in all
- Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant RecipientsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00113269 · 501 participants · Start May 2005 · Primary completion Mar 2009
Drug: basiliximab; rabbit anti-thymocyte globulin and 4 more · For: Kidney Transplantation
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 29 sites in all
- Different Therapies in Treating Infants With Newly Diagnosed Acute LeukemiaPivotal-lookingStatus unknown
Dutch Childhood Oncology GroupAcademic, hospital or other
NCT00550992 · 445 participants (planned) · Start Jan 2006 · Primary completion Dec 2020
Drug: anti-thymocyte globulin; asparaginase and 17 more · For: Leukemia
Sites: Boston, Massachusetts; Memphis, Tennessee; Houston, Texas · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Vitamin D deficiency is common in Hashimoto's thyroiditis, while VDR FokI shows subtype-specific association with gravis disease in Jordan: a case-control study.
Tout FS, Batayneh S, Alsaheb Y · Clin Chim Acta 2027
- Management strategy in aplastic anemia patients with HBV infection following intensive immunosuppressive therapy in Chinese cohort: prophylactic antiviral therapy may not be necessary with close monitoring.
Zhang Y, Chen X, Zhang T, et al. · Hematology 2026
- Motor City autophagy.
Klionsky DJ · Autophagy 2026
- Transcriptional control of autophagy: mechanisms, dynamics, and pharmacological modulation.
Qin W, Yang L, Deng X, et al. · Autophagy 2026
- Mitogenomic Architecture and Phylogenetic Insights Shed Light on the Matrilineal Evolution of the Mahseer Fish Neolissochilus sumatranus (Cyprinidae: Torinae) in Southeast Asia.
Larashati S, Putra A, Aini S, et al. · Biochem Genet 2026
- Clonal Dynamics of GPI-Deficient Cells in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Follow-Up Analysis.
Frey SM, Poppenborg F, Schmücker U, et al. · Eur J Haematol 2026
Also in development for Transplant Rejection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.